News | June 18, 2012

Data Suggest Convergent Procedure Ablation May Restore Persistent AFib Patients to Normal Sinus Rhythm

Physician presentations at Heart Rhythm 2012 highlight new 12-plus month data, with more than 80 percent in sinus rhythm

June 18, 2012 — Epicardial ablation device maker Contact Inc. announced that new long-term physician data demonstrated promising clinical outcomes for the multidisciplinary convergent procedure in the treatment of persistent atrial fibrillation (AF), with more than 80 percent of patients remaining in sinus rhythm at a minimum of 12 months follow-up. The data was presented by physicians at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions in May. 

During the oral abstract sessions, a presentation by Kenneth C. Civello, M.D., Our Lady of the Lake Medical Center, Baton Rouge, La., highlighted clinical outcomes from 104 consecutive patients treated with the convergent procedure. Of these, 73 percent suffered with persistent or permanent AF. Results demonstrated that 86 percent of patients who reached six months follow-up were in sinus rhythm, with 78 percent in sinus rhythm off anti-arrhythmic drugs (AADs). Of the 40 patients who have reached 12 month follow-up, 81 percent were in sinus rhythm, with 69 percent in sinus rhythm off AADs.

A poster presented by David M. Gilligan, M.D., Levinson Heart Hospital at CJW Medical Center, Richmond, Va., reviewed data from a prospective registry of the first 39 patients to undergo ablation with the convergent procedure at the center, 79 percent of whom suffered with persistent or longstanding persistent AF. At 12 months post procedure, 96 percent of patients were in sinus rhythm with nearly 70 percent in sinus rhythm off AADs.

A poster presented by Keith M. Golden, M.D., St. Vincent Hospital, Indianapolis, Ind. demonstrated positive outcomes on 60 patients undergoing the convergent procedure, considering 88 percent of patients had persistent or longstanding persistent AF. This was a difficult cohort of patients with enlarged left atria, and an average BMI over 35. At an average follow up of 11 months (333 +/- 156 days), 79 percent of patients were in sinus rhythm.  Notably, this continued to hold true for the 14 patients who reached 18 months follow-up, with 79 percent remaining in sinus rhythm, all of whom were also off AADs.

The various posters and presentations reaffirmed the ability of the convergent procedure to achieve consistent single procedure results across hospital sites. The potential advantage of the convergent procedure is that it integrates the best practices of surgeons and electrophysiologists in a single setting, utilizing a minimally invasive, trans-diaphragmatic approach for direct access to the posterior of the left atrium without chest incisions, lung deflation or cardiac dissections. Developed by physicians and enabled by nContact's epicardial ablation technology, it has been shown to be especially appropriate for AF patients with enlarged atria and persistent or long-standing persistent stages of disease.

For more information: 

Related Content

Stereotaxis Receives Regulatory Approval of e-Contact Module in Canada
Technology | Ablation Systems | December 08, 2017
December 7, 2017 — Stereotaxis Inc.
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems | October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems | October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems | August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems | July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems | May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems | May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems | February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
CardioFocus, HeartLight Excalibur Balloon, 22nd Annual AF Symposium, atrial fibrillation, initial clinical evaluation
News | Ablation Systems | January 25, 2017
CardioFocus Inc. recently announced the initial clinical evaluation of the HeartLight Excalibur Balloon, a next-...
catheter ablations, atrial fibrillation, stroke risk, Intermountain Medical Center Heart Institute study, AHA Scientific Sessions, American Heart Association
News | Ablation Systems | November 14, 2016
Atrial fibrillation patients with a prior history of stroke who undergo catheter ablation lower their long-term risk of...
Overlay Init